MoonLake Immunotherapeutics
MLTX
147 hedge funds and large institutions have $1.17B invested in MoonLake Immunotherapeutics in 2026 Q1 according to their latest regulatory filings, with 40 funds opening new positions, 49 increasing their positions, 43 reducing their positions, and 21 closing their positions.
265% more call options, than puts
Call options by funds: $34M | Put options by funds: $9.32M
90% more first-time investments, than exits
New positions opened: 40 | Existing positions closed: 21
58% more capital invested
Capital invested by funds: $743M → $1.17B (+$430M)
14% more repeat investments, than reductions
Existing positions increased: 49 | Existing positions reduced: 43
13% more funds holding
Funds holding: 130 → 147 (+17)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
0.57% less ownership
Funds ownership: 88.47% → 87.9% (-0.57%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MB
MPM BioImpact
Boston,
Massachusetts
|
+$30M |
| 2 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$29.8M |
| 3 |
WAM
Weiss Asset Management
Boston,
Massachusetts
|
+$22.8M |
| 4 |
Janus Henderson Group
London,
|
+$22.5M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$15.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
-$62.1M |
| 2 |
Jane Street
New York
|
-$20.3M |
| 3 |
Nuveen
Charlotte,
North Carolina
|
-$10M |
| 4 |
Balyasny Asset Management
Chicago,
Illinois
|
-$8.37M |
| 5 |
Morgan Stanley
New York
|
-$7.12M |
MLTX Hedge Fund Activity: Q1 2026 in Review
147 of the 8,191 institutional investors tracked by Wall St. Rank reported a position in MoonLake Immunotherapeutics (MLTX) for Q1 2026, worth a combined $1.17B — up 58% from $743M a quarter earlier.
Buyers outnumbered sellers: 40 funds opened new MLTX positions and 21 closed out — a net gain of 19 holders — while 49 added to existing stakes and 43 trimmed.
The largest buyer was MPM BioImpact, opening a new position worth an estimated $30M. The largest seller was BVF Inc, cutting an estimated $62.1M.
- 147 institutional investors held MoonLake Immunotherapeutics (MLTX) as of Q1 2026, up from 130 in Q4 2025.
- Funds reported $1.17B of MoonLake Immunotherapeutics stock for Q1 2026, up 58% quarter-over-quarter.
- 40 funds opened new MoonLake Immunotherapeutics positions in Q1 2026 and 21 closed out, a net change of +19 holders.
- The largest MoonLake Immunotherapeutics buyer in Q1 2026 was MPM BioImpact, an estimated $30M added.
- The largest MoonLake Immunotherapeutics seller in Q1 2026 was BVF Inc, an estimated $62.1M sold.
Based on aggregated 13F filings for Q1 2026.